Keywords: AVEO, Biogen, ErbB3, Milestone, Antibody

AVEO Pharma gets $5 million milestone as Biogen selects first candidate under ErbB3 antibody program

Article | 15 April 2010

USA-based cancer orientated biopharmaceutical firm AVEO Pharmaceuticals says it has received a $5 million milestone payment from Biogen Idec International GmbH, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Biogen Idec

AVEO Pharmaceuticals

Go to company listing